Andrew Tutt, MB ChB, PhD, director of the breast cancer research teams at The Institute of Cancer Research in London, talks with Julie Nangia, MD, about the results of the phase 3 OlympiA trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1 and BRCA2 pathogenic variants and high-risk HER2-negative primary breast cancer.